In China, Phase 2 Study of Relma-Cel in R/R MCL Finds Durable Responses

Why It Matters

Relma‑cel addresses a critical unmet need for durable, off‑the‑shelf CAR‑T therapy in a high‑risk Chinese MCL population, potentially reshaping the national treatment paradigm.

Key Takeaways

• ORR 71% and CRR 59% in heavily pre‑treated Chinese MCL.
• Median response time under one month, durability 18‑month median.
• Grade ≥ 3 neutropenia 76%; CRS 81% (grade ≥ 3 6.8%).
• No treatment‑related deaths; COVID‑19 impacted overall survival data.
• First CD19 CAR‑T likely approved for R/R MCL in China.

Pulse Analysis

Mantle‑cell lymphoma (MCL) remains one of the most aggressive non‑Hodgkin lymphomas, with relapse rates soaring after conventional chemoimmunotherapy. The introduction of Bruton tyrosine kinase (BTK) inhibitors extended survival, yet patients who progress on BTK‑targeted regimens face median overall survivals of less than a year. Globally, CD19‑directed CAR‑T therapies such as brexucabtagene autoleucel and lisocabtagene maraleucel have demonstrated high response rates, but regulatory approval and market access have lagged in China, leaving a therapeutic vacuum for heavily pre‑treated MCL patients.

The relma‑cel phase‑2 data bridge that gap, delivering an ORR of 71% and a CRR of 59% in a cohort characterized by BTK‑inhibitor refractory disease, blastoid histology, and extensive prior therapy. Notably, the median time to first response was under one month, underscoring rapid disease control, while the median duration of response of 18.1 months rivals outcomes from the US‑based ZUMA‑2 and TRANSCEND trials. Safety signals align with class‑effects: high‑grade neutropenia and CRS were common, yet all events resolved and no treatment‑related fatalities were recorded, suggesting a manageable risk profile when paired with vigilant supportive care.

For Chinese oncology practice, relma‑cel could become the first domestically approved CD19 CAR‑T for MCL, simplifying logistics compared with imported products and potentially lowering costs. The trial’s multicenter design across 17 sites demonstrates feasibility of large‑scale manufacturing and delivery within China’s healthcare infrastructure. However, the high incidence of severe infections and the confounding impact of COVID‑19 on overall survival highlight the need for robust infection prophylaxis and longer follow‑up. If subsequent studies confirm these findings, relma‑cel may shift standard of care from salvage chemotherapy toward cellular immunotherapy for a patient segment that currently lacks curative options.